Replies to post #31604 on Ayala Pharmaceuticals Inc (ADXS)

[ignatiusrielly35]

"My point is you cannot assume equity funding is less preferable to partnering or vice versa."

Fair enough, Meisha. It does depend on the specific numbers. And my point is that equity dilution dilutes all indications/markets simultaneously, instead of individually, and unless the share price recovers by several multiples from here it would be foolish to dilute with additional shares. I would guess that virtually everyone here agrees, and so, apparently, do the tutes and the BODs.

As to the timing of an EMA decision, the issue I had with your mid-2019 prediction was that you said that was the best-case scenario. Now that you've clarified that it is actually the worst-case scenario--the best case being mid-2018--we are in agreement.

[CATTDOGG12347]

In all honesty, I think we can look at Dan O'Connor and glean a lot from his leaving. He'll get paid for another 10-11 months sitting and doing literally nothing. The whole time Dan was at Advaxis his primary concern was grabbing as many shares as he could get his hands on. He and the rest of management grabbed a boat load at the last annual meeting with 40% of investors voting against it. This action was approved by the BOD so Dan wasn't fired for that. A short time later Dan resigned grabbing more shares via his separation contract. All this after BMY came in and before EU submission.
I think what we can learn from this is we have an enormous amount of news coming in the next 10 months and probably next few months. There's no way Dan would have left if he thought he could have bled the company for more via another route given the time frame! JMO